60th ASH Annual Meeting & Exposition Poster & Lecture Presentations

Presenter	Role	Oral Presentation/Poster	Title
Mahi Lab	UVA study	Oral	The PIM Kinase inhibitor TP-3652 in combo with ruxolitin ib exhibits improvement in MF in murine models
Gru	Co-Aut hor	Poster	Superior clinical benefit of Brentux Vedotin in MF vs. Physician’s choice irrespective of CD30 or Lg cell txf status in Phase 3 ALCANZA study.
Reed et al Keng Sr	UVA study	Poster	Oral regimen for urine alka lization in Pts getting HD MTX during shortage of IV bicarb
Grose et al Douvas Sr	UVA study	Poster	Decrease of asparaginase induced thrombotic events with ATIII monitoring and repletion
Leslie M et al Davidson Sr	UVA study	Poster	Econsultation to hematologist from primary care: an assessment of content and Pt impact
Ballen	Co-Author	Poster	Lost to follow up rates higher in peds than adult survivors, but not Txpl type: report fro CIBMTR
Mahi Lab	UVA study	Poster	The NF-kB inhib DMAPT in combo with Ruxolitinib has efficacy in JAK2 V617F knock-in mouse model of MPN
Ballen	Co-Author	Poster	Phase I Brentux Vedotin with chemo as re-induction for CD30+ r/r AML
Bushweller lab	UVA study	Poster	Direct binding of BCOR, but not CBX8, to MLL-AF9 is essential for MLL leukemia via regulation of EYA1/ SIX1
Orellana- Noia/Portell	Co-Authors Oral	4:30-6:00 Ballroom 20D	Outcome of Pts with aggressive B-cell lymphoma post salvage immunochemo following intensive first line Rx
Goldfarb lab	UVA study	Poster	Dysregulation of RUNX3 in aged human HSPCs may cont ribute to perturbation sin erythropoies is and balanced lineage output.
Jayappa et al	UVA study	Poster	Drug combos co-targeting MCL-1 can overcome microenvironmentally-induced drug tolerance in NHLs
Arora et al Williams Sr	UVA study	Poster	Single institution experience of GI involved DLBCL: presentat ion , outcomes, and Patterns of Rx failure
Abraham et al Maitland Sr	UVA study	Poster	Bleeding risk of LMW heparin vs. DOAC in pts with intracranial tumors
Grose et al Volodin Sr	UVA study	Poster	Cipro prophy does not affect incidence of c.diff infection in auto SCT Pts.
Ballen	Co-Au thor	Poster	Phase I stu dy of ixazomib + chemo for ALL in older adults
Ballen	Co-Author Oral	2:45-4:15p Seaport Blrm F	Phase II clinical trial of alisertib (arora kinase inhib) in combo with induction chemo in AML
Ballen	Co-Author Oral	6:15-7:45p Seaport Blrm A	T-replete Haplo Txpl using post-txpl Cytoxan for AML, ALL, MOS: effect of Txpl conditioning regimen intensity
Lee	Co-Author Oral	4:30-6:00p San Diego Blrm B (Marriott)	Low CD19 Ag density Diminishes Efficacy of CD19 CART- cells and can be overcome by redesign of CAR signaling domains
Williams	Moderator	7:00-8:30A	CLL: Biology and pathophysiology, excluding therapy: Mechanisms of action and resistance to targeted agents
Weber	Moderator	4:30-6:00p Room 29C	Molecular pharmacology, drug resistance-lymphoid and other disorders: molecular Mechanisms in Leukemic drug resistance
Garrett- Bakelman	Presenter/ Panelist	4:30-6:00 p Room28D	Fran will be highlighting her research as a ASH supported research in this special interest sessionI
Jayappa et al	UVA study	Poster	A Multi-drug tolerant phenotype is induced by diverse microenvironmental agonist in CLL and MCL
Mehra/Portell	Co-Author	Poster	Outcomes of FL Pts treated with frontline BR: impact of histologic grade and early progression on OS
Gade etal Maitland Sr	UVA Study	Poster	A Single institution’s adherence to hep-induced TCP and Thrombosis testing guidelines
Keng	Presenter and 151 auth	Poster	Planned interim analysis of Phll study of Practinostat and A2A in Pts with high/very high risk MOS
Garret- Bakelman	Co-Author	Poster	Therapeutic targeting of ubiquitin conjugating enzyme UBE2N in myeloid malignancies
Ballen	Co-Author	Poster	Efficacy of Len and Bortez for AML or MOS relapse post AlloSCT
Ballen	Co-Author	Poster	Survival advantage to allo SCT in MF with>/= lnt-1DIPSS